

Barbara Arias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2003224/publications.pdf>

Version: 2024-02-01

73
papers

2,946
citations

186265

28
h-index

175258

52
g-index

85
all docs

85
docs citations

85
times ranked

4833
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. <i>Lancet, The</i> , 2016, 387, 1085-1093.	13.7	306
2	Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. <i>Psychological Medicine</i> , 2009, 39, 1425-1432.	4.5	237
3	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. <i>Human Molecular Genetics</i> , 2016, 25, 3383-3394.	2.9	182
4	Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. <i>Journal of Affective Disorders</i> , 2007, 104, 83-90.	4.1	165
5	5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 563-567.	1.4	156
6	Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like experiences. <i>British Journal of Psychiatry</i> , 2011, 199, 38-42.	2.8	103
7	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. <i>JAMA Psychiatry</i> , 2018, 75, 65-74.	11.0	102
8	Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. <i>Journal of Affective Disorders</i> , 2006, 90, 251-256.	4.1	93
9	Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. <i>Journal of Psychopharmacology</i> , 2005, 19, 166-172.	4.0	88
10	The 5-HT2A receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 801-804.	2.4	74
11	Association analysis between a functional polymorphism in the monoamine oxidase A gene promoter and severe mood disorders. <i>Psychiatric Genetics</i> , 2004, 14, 203-208.	1.1	69
12	Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. <i>Journal of Medical Genetics</i> , 2004, 41, 219-223.	3.2	67
13	Variability in the 5-HT2A receptor gene is associated with seasonal pattern in major depression. <i>Molecular Psychiatry</i> , 2001, 6, 239-242.	7.9	64
14	Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression. <i>Psychopharmacology</i> , 2011, 216, 1-8.	3.1	58
15	Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 54-62.	4.5	54
16	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. <i>Psychopharmacology</i> , 2013, 227, 509-519.	3.1	51
17	Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT1A receptor gene as putative risk factors in major depression. <i>Molecular Psychiatry</i> , 2002, 7, 930-932.	7.9	50
18	Impact of childhood trauma on cognitive profile in bipolar disorder. <i>Bipolar Disorders</i> , 2017, 19, 363-374.	1.9	49

#	ARTICLE	IF	CITATIONS
19	Impulsivity and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2012, 136, 491-497.	4.1	47
20	Genetic variability at IMPA2, INPP1 and GSK3 β increases the risk of suicidal behavior in bipolar patients. <i>European Neuropsychopharmacology</i> , 2013, 23, 1452-1462.	0.7	46
21	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. <i>Molecular Psychiatry</i> , 2021, 26, 2457-2470.	7.9	44
22	The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety-related traits. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 194-202.	4.5	41
23	Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 26-31.	4.8	37
24	Polygenic determinants of white matter volume derived from GWAS lack reproducibility in a replicate sample. <i>Translational Psychiatry</i> , 2014, 4, e362-e362.	4.8	35
25	Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 266-276.	4.5	35
26	TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression. <i>Neuropsychobiology</i> , 2013, 67, 41-47.	1.9	30
27	Childhood maltreatment and risk for suicide attempts in major depression: a sex-specific approach. <i>HÅrgre Utbildning</i> , 2019, 10, 1603557.	3.0	29
28	Dermatoglyphics and abnormal palmar flexion creases as markers of early prenatal stress in children with idiopathic intellectual disability. <i>Journal of Intellectual Disability Research</i> , 2001, 45, 416-423.	2.0	28
29	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 207.	2.6	28
30	Genetic variation in the 5-HT $2A$ receptor gene in patients with bipolar disorder and major depression. <i>Neuroscience Letters</i> , 2001, 303, 111-114.	2.1	27
31	Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes. <i>Journal of Psychopharmacology</i> , 2012, 26, 1391-1398.	4.0	26
32	Regional gray matter reductions are associated with genetic liability for anxiety and depression: An MRI twin study. <i>Journal of Affective Disorders</i> , 2013, 149, 175-181.	4.1	26
33	Association between GSK3 β gene and increased impulsivity in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2014, 24, 510-518.	0.7	25
34	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. <i>Translational Psychiatry</i> , 2021, 11, 606.	4.8	25
35	Association study between novel promoter variants at the 5-HT $2C$ receptor gene and human patients with bipolar affective disorder. <i>Neuroscience Letters</i> , 2001, 309, 135-137.	2.1	24
36	Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 121-128.	1.5	24

#	ARTICLE	IF	CITATIONS
37	Acquisition and generalization of fear conditioning are not modulated by the BDNF Val66Met polymorphism in humans. <i>Psychophysiology</i> , 2012, 49, 713-719.	2.4	23
38	Dysbindin 1 gene contributes differentially to early and adult onset forms of functional psychosis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 322-333.	1.7	22
39	Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 600-604.	1.4	20
40	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. <i>Bipolar Disorders</i> , 2019, 21, 68-75.	1.9	20
41	Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits. <i>Neuroscience Letters</i> , 2004, 363, 78-80.	2.1	19
42	Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients. <i>NeuroImage</i> , 2011, 56, 45-51.	4.2	19
43	Hypothalamic-pituitary-adrenal system, neurotrophic factors and clozapine response. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 274-277.	1.5	19
44	BDNF as a marker of response to cognitive remediation in patients with schizophrenia: A randomized and controlled trial. <i>Schizophrenia Research</i> , 2018, 197, 458-464.	2.0	19
45	Further Evidence That Congenital Dermatoglyphic Abnormalities Are Associated With Psychosis: A Twin Study. <i>Schizophrenia Bulletin</i> , 2002, 28, 697-701.	4.3	17
46	Characterizing decision-making and reward processing in bipolar disorder: A cluster analysis. <i>European Neuropsychopharmacology</i> , 2018, 28, 863-874.	0.7	16
47	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. <i>Journal of Affective Disorders</i> , 2014, 168, 91-97.	4.1	15
48	Research Letter: Childhood trauma and the rs1360780 SNP of FKBP5 gene in psychosis: a replication in two general population samples. <i>Psychological Medicine</i> , 2016, 46, 221-223.	4.5	15
49	The BDNF-Val66Met polymorphism modulates parental rearing effects on adult psychiatric symptoms: A community twin-based study. <i>European Psychiatry</i> , 2014, 29, 293-300.	0.2	14
50	Do FSH/LH ratio and gonadal hormone levels predict clinical improvement in postmenopausal schizophrenia women?. <i>Archives of Women's Mental Health</i> , 2017, 20, 613-620.	2.6	14
51	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. <i>Schizophrenia Research</i> , 2017, 189, 196-203.	2.0	13
52	Risk of Suicidal Behavior in Children and Adolescents Exposed to Maltreatment: The Mediating Role of Borderline Personality Traits and Recent Stressful Life Events. <i>Journal of Clinical Medicine</i> , 2021, 10, 5293.	2.4	13
53	Psychometric Properties of Drinking Motives Questionnaire-Revised (DMQ-R) in Spanish Adolescents. <i>European Journal of Psychological Assessment</i> , 2018, 34, 145-153.	3.0	12
54	The interaction between the ZNF804A gene and cannabis use on the risk of psychosis in a non-clinical sample. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 174-180.	4.8	11

#	ARTICLE	IF	CITATIONS
55	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. <i>British Journal of Psychiatry</i> , 2022, 220, 219-228.	2.8	11
56	Role of neurotrophins in depressive symptoms and executive function: Association analysis of NRN1 gene and its interaction with BDNF gene in a non-clinical sample. <i>Journal of Affective Disorders</i> , 2017, 211, 92-98.	4.1	10
57	Evidence of an Epistatic Effect Between Dysbindin-1 and Neuritin-1 Genes on the Risk for Schizophrenia Spectrum Disorders. <i>European Psychiatry</i> , 2017, 40, 60-64.	0.2	10
58	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. <i>Scientific Reports</i> , 2021, 11, 17823.	3.3	10
59	Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLIM): justificación, objetivos, diseño y descripción de la muestra. <i>Revista De Psiquiatría Y Salud Mental</i> , 2014, 7, 166-178.	1.8	9
60	Predicting Response Trajectories during Cognitive-Behavioural Therapy for Panic Disorder: No Association with the BDNF Gene or Childhood Maltreatment. <i>PLoS ONE</i> , 2016, 11, e0158224.	2.5	9
61	Season of birth and subclinical psychosis: Systematic review and meta-analysis of new and existing data. <i>Psychiatry Research</i> , 2015, 225, 227-235.	3.3	8
62	Association between genetic variation in the myo-inositol monophosphatase 2 (IMPA2) gene and age at onset of bipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 232, 229-236.	4.1	8
63	The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies. <i>NPJ Schizophrenia</i> , 2017, 3, 40.	3.6	7
64	Association between symptomatic profile and remission following antidepressant treatment in unipolar major depression. <i>Journal of Affective Disorders</i> , 2013, 150, 209-215.	4.1	6
65	Human genetic variation and mental disorders. <i>Neurotoxicity Research</i> , 2002, 4, 523-530.	2.7	5
66	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, , .	1.8	3
67	NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7456.	4.1	2
68	FC12.03 Recent dermatoglyphic studies in twin samples: Further evidences for an environmental risk factor in schizophrenia. <i>European Psychiatry</i> , 2000, 15, 305s-306s.	0.2	0
69	GENETIC VARIABILITY IN DYSBINDIN-1 GENE (DTNBP1) CONTRIBUTES DIFFERENTIALLY TO EARLY AND ADULT ONSET FUNCTIONAL PSYCHOSES AND IT IS ASSOCIATED WITH THE FAMILIAL TRANSMISSION OF IQ AND PREFRONTAL COGNITIVE DEFICITS. <i>Schizophrenia Research</i> , 2010, 117, 220-221.	2.0	0
70	Childhood Abuse and the BDNF-Val66Met Polymorphism: Evidence for Gene-Environment Interaction in the Development of Adult Psychosis-Like Experiences. <i>European Psychiatry</i> , 2011, 26, 1381-1381.	0.2	0
71	Poster #2 CHILDHOOD ADVERSITY AND CANNABIS USE IN THE DEVELOPMENT OF POSITIVE PSYCHOTIC-LIKE EXPERIENCES: MODERATION EFFECTS OF THE COMT GENE. <i>Schizophrenia Research</i> , 2012, 136, S91.	2.0	0
72	Combining fMRI and DISC1 gene haplotypes to understand working memory-related brain activity in schizophrenia. <i>Scientific Reports</i> , 2022, 12, 7351.	3.3	0

#	ARTICLE	IF	CITATIONS
73	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Revista De Psiquiatr�a Y Salud Mental (English) Tj ETQq1 1 0.784314 rgBT /Over		